open access

Vol 8, No 1 (2002)
Original papers
Published online: 2002-02-07
Get Citation

The cyclic guanosine 3’-, 5’-monophosphate concentration and estrogens in women with primary hypotonia

Stanisław Stanosz, Piotr Bartoszczuk, Krzysztof Sieja, Grażyna Justyńska, Małgorzata Stanosz
Acta Angiologica 2002;8(1):29-35.

open access

Vol 8, No 1 (2002)
Original papers
Published online: 2002-02-07

Abstract

Introduction. The cyclic guanosine 3’-, 5’-monophosphate (cGMP) is the strongest natural endothelium vasodilating factor, but its function as the “second messenger” is less recognised than the cyclic AMP function. It is known that this compound has a significance in retina function, regulation of the blood vessel smooth muscle tone, trachea and bronchia, inhibition of thrombocyte adhesion and aggregation, neuromodulation and neurotransmission, and the atrial natriuretic peptide function. The physiological activator of cyclic GMP is the endothelial-derived relaxant factor (EDRF) –– nitric oxide (NO).
Aim of study. The aim of this thesis is an estimation of the cyclic GMP concentration in women’s hypotonia, and a determination of the dependence between cGMP concentrations and systolic, diastolic and medium arterial blood pressure (MAP) and estrogen concentrations.
Material and methods. The study included 80 women, 40–50 years old, with negative medical history, divided into two groups. The first (control) group consisted of 19 women with regular arterial blood pressure. The second (examined) group included 61 women with hypotonia, with systolic arterial blood pressure not higher than 105 mm Hg (14.7 kPa). The subject of estimation was the average value of systolic, diastolic and medium arterial blood pressure (MAP). The biological material for cyclic GMP determination was blood. The cGMP concentration was determined by the immunoenzymatic method, with AMERSHAM set. The obtained results were put to statistical analysis, with the Statistica computer program, using U Mann Whitney’s Test as statistically significant when p Ł 0.05.
Results. Cyclic GMP concentration in women with arterial hypotension comparing to control group was significantly higher (p < 0.0001). There were no differences in estron (E1) concentration between control and examined group. Estradiol (E2) concentrations in women with hypotonia comparing to control group were not significantly higher (p > 0.29). The line correlation coefficients “r” between cyclic GMP concentration and systolic, diastolic and medium (MAP) arterial blood pressure, both in women with regular blood pressure andhypotonia, were not significantly different.
Conclusions. High significant (p < 0.0001) cGMP concentration in women with hypotonia can speak for its increased synthesis or defective degradation. In women with hypotonia high significant cGMP concentrations can speak for its part in the pathogenesis and course of arterial hypotonia.

Abstract

Introduction. The cyclic guanosine 3’-, 5’-monophosphate (cGMP) is the strongest natural endothelium vasodilating factor, but its function as the “second messenger” is less recognised than the cyclic AMP function. It is known that this compound has a significance in retina function, regulation of the blood vessel smooth muscle tone, trachea and bronchia, inhibition of thrombocyte adhesion and aggregation, neuromodulation and neurotransmission, and the atrial natriuretic peptide function. The physiological activator of cyclic GMP is the endothelial-derived relaxant factor (EDRF) –– nitric oxide (NO).
Aim of study. The aim of this thesis is an estimation of the cyclic GMP concentration in women’s hypotonia, and a determination of the dependence between cGMP concentrations and systolic, diastolic and medium arterial blood pressure (MAP) and estrogen concentrations.
Material and methods. The study included 80 women, 40–50 years old, with negative medical history, divided into two groups. The first (control) group consisted of 19 women with regular arterial blood pressure. The second (examined) group included 61 women with hypotonia, with systolic arterial blood pressure not higher than 105 mm Hg (14.7 kPa). The subject of estimation was the average value of systolic, diastolic and medium arterial blood pressure (MAP). The biological material for cyclic GMP determination was blood. The cGMP concentration was determined by the immunoenzymatic method, with AMERSHAM set. The obtained results were put to statistical analysis, with the Statistica computer program, using U Mann Whitney’s Test as statistically significant when p Ł 0.05.
Results. Cyclic GMP concentration in women with arterial hypotension comparing to control group was significantly higher (p < 0.0001). There were no differences in estron (E1) concentration between control and examined group. Estradiol (E2) concentrations in women with hypotonia comparing to control group were not significantly higher (p > 0.29). The line correlation coefficients “r” between cyclic GMP concentration and systolic, diastolic and medium (MAP) arterial blood pressure, both in women with regular blood pressure andhypotonia, were not significantly different.
Conclusions. High significant (p < 0.0001) cGMP concentration in women with hypotonia can speak for its increased synthesis or defective degradation. In women with hypotonia high significant cGMP concentrations can speak for its part in the pathogenesis and course of arterial hypotonia.
Get Citation

Keywords

hypotonia arterialis; blood pressure; cyclic GMP; estrogens; nitric oxide; vessel endothelium smooth muscle

About this article
Title

The cyclic guanosine 3’-, 5’-monophosphate concentration and estrogens in women with primary hypotonia

Journal

Acta Angiologica

Issue

Vol 8, No 1 (2002)

Pages

29-35

Published online

2002-02-07

Bibliographic record

Acta Angiologica 2002;8(1):29-35.

Keywords

hypotonia arterialis
blood pressure
cyclic GMP
estrogens
nitric oxide
vessel endothelium smooth muscle

Authors

Stanisław Stanosz
Piotr Bartoszczuk
Krzysztof Sieja
Grażyna Justyńska
Małgorzata Stanosz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl